We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

0 hedge funds and large institutions have $0 invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 130 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 130 → 0 (-130)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $3.89B → $0 (-$3.89B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 130

Holders
–
Holders Change
-130
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
130
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$1.14B
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$541M
3
Capital Research Global Investors
Capital Research Global Investors
California
-$442M
4
CWAM
Columbia Wanger Asset Management
Illinois
-$317M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$152M
Name Holding Trade Value Shares
Change 		Change in
Stake
Swiss National Bank
51
Swiss National Bank
Switzerland
– -$2.78M -28,530 Closed
Asset Management One
52
Asset Management One
Japan
– -$2.71M -27,200 Closed
N
53
Nuveen
North Carolina
– -$2.55M -26,158 Closed
TD Asset Management
54
TD Asset Management
Ontario, Canada
– -$2.47M -25,300 Closed
Citigroup
55
Citigroup
New York
– -$2.41M -24,725 Closed
NLVP
56
New Leaf Venture Partners
New York
– -$2.38M -24,379 Closed
MOACM
57
Mutual of America Capital Management
New York
– -$2.37M -24,304 Closed
RhumbLine Advisers
58
RhumbLine Advisers
Massachusetts
– -$2.36M -24,195 Closed
MAA
59
Managed Account Advisors
New Jersey
– -$2.32M -23,762 Closed
Barclays
60
Barclays
United Kingdom
– -$1.93M -19,907 Closed
American Century Companies
61
American Century Companies
Missouri
– -$1.84M -18,904 Closed
AA
62
ALPS Advisors
Colorado
– -$1.8M -18,432 Closed
MLICM
63
Metropolitan Life Insurance Company (MetLife)
New York
– -$1.74M -17,857 Closed
OPPM
64
Opus Point Partners Management
New York
– -$1.73M -17,700 Closed
State Board of Administration of Florida Retirement System
65
State Board of Administration of Florida Retirement System
Florida
– -$1.72M -17,620 Closed
DekaBank Deutsche Girozentrale
66
DekaBank Deutsche Girozentrale
Germany
– -$1.69M -17,310 Closed
NFA
67
Nationwide Fund Advisors
Ohio
– -$1.66M -16,994 Closed
Deutsche Bank
68
Deutsche Bank
Germany
– -$1.55M -15,957 Closed
Morgan Stanley
69
Morgan Stanley
New York
– -$1.54M -15,826 Closed
Manulife (Manufacturers Life Insurance)
70
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$1.51K -15,501 Closed
BAMS
71
Bellevue Asset Management (Switzerland)
Switzerland
– -$1.45M -14,900 Closed
AIG
72
American International Group
New York
– -$1.31M -13,465 Closed
WSA
73
Wall Street Associates
California
– -$1.21M -12,428 Closed
VOYA Investment Management
74
VOYA Investment Management
Georgia
– -$1.15M -11,737 Closed
EU
75
Emory University
Georgia
– -$961K -9,854 Closed
1 2
3
4 5

GEVA Hedge Fund Activity: Q2 2015 in Review

0 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q2 2015, worth a combined $0 — down 100% from $3.89B a quarter earlier.

Sellers outnumbered buyers: 130 funds closed out of GEVA and 0 opened new positions — a net loss of 130 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.14B sold.

  • 0 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q2 2015, down from 130 in Q1 2015.
  • Funds reported $0 of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q2 2015, down 100% quarter-over-quarter.
  • 0 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q2 2015 and 130 closed out, a net change of -130 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q2 2015 was Baker Bros. Advisors, an estimated $1.14B sold.

Based on aggregated 13F filings for Q2 2015.